<DOC>
	<DOCNO>NCT02428309</DOCNO>
	<brief_summary>The primary purpose Phase 1 study evaluate safety , tolerability , effect 3 different dos Treg therapy adult skin ( cutaneous ) involvement lupus . Targeting cutaneous disease offer ability control background therapy , readily detect clinical effect , perform research analysis blood also skin . Safety , disease activity , mechanism Tregs evaluate . The intent support dose selection future large efficacy trial lupus .</brief_summary>
	<brief_title>Autologous Polyclonal Tregs Lupus</brief_title>
	<detailed_description>The investigational therapy trial , regulatory T cell ( Tregs ) , evaluate alternative traditional immunosuppressive therapy treatment systemic lupus erythematosus ( SLE , lupus ) . Too frequently , aggressive therapy inadequate control disease potent side effect complication . The collection expansion one 's T cell harness naturally occur regulatory mechanism restore self-tolerance people lupus . Tregs specialize subset T cell function control immune response . Studies show active lupus , number function Treg cell significantly decrease , contribute overactive immune system increase disease activity . The hope naturally occur Treg cell use treatment autoimmune disease , include lupus .</detailed_description>
	<mesh_term>Lupus Erythematosus , Systemic</mesh_term>
	<mesh_term>Lupus Erythematosus , Cutaneous</mesh_term>
	<mesh_term>Lupus Erythematosus , Discoid</mesh_term>
	<criteria>Ability provide inform consent . Diagnosis SLE American College Rheumatology ( ACR ) criteria biopsy proven primary cutaneous lupus . Presence ≥ 2 active cutaneous lupus lesion base ( 1 ) visual morphology ( 2 ) least grade 2 erythema CLASI activity score . Histopathologic confirmation require unless active lesion morphology previously histologically proven cutaneous lupus lesion . The cutaneous lupus lesion must include follow subtypes : Acute cutaneous lupus include maculopapular lupus rash photosensitive lupus rash , Subacute cutaneous lupus , Chronic cutaneous lupus include discoid lupus hypertrophic ( verrucous ) lupus , Lupus timidus Positive test EpsteinBarr virus ( EBV ) antibody . Adequate venous access support draw 400 mL whole blood infusion investigational therapy . New onset cutaneous lupus treat broad spectrum sunscreen ( UVA UVB ) combination either antimalarial another systemic medication least 3 month . Prednisone dose &gt; 15mg/day within 30 day prior screen . Addition new medication , change dose background medication , use treat aspect SLE . Specifically : addition change systemic glucocorticoid , antimalarial , methotrexate , mycophenolate mofetil , mycophenolic acid , azathioprine , cyclosporine , tacrolimus , thalidomide , lenalidomide , dapsone , acitretin , isotretinoin within 90 day prior screen treatment cyclophosphamide within 90 day prior screen . Doses background medication Screening visit : hydroxychloroquine &gt; 400 mg/day , chloroquine &gt; 250 mg/day , quinacrine &gt; 100 mg/day , methotrexate &gt; 25 mg/week , mycophenolate mofetil ( MMF ) &gt; 3000 mg/day , mycophenolic acid &gt; 720 mg/day BID , azathioprine &gt; 200 mg/day , cyclosporine &gt; 5 mg/day divide BID , tacrolimus &gt; 6 mg/day thalidomide &gt; 300 mg/day , lenalidomide &gt; 10 mg/day , dapsone &gt; 250 mg/day , acitretin &gt; 50 mg/d ( &gt; 1 mg/kg/day ) , isotretinoin &gt; 120 mg/d ( &gt; 2 mg/kg/day ) . Intravenous immunoglobulin ( IVIG ) , plasmapheresis , leukopheresis within 90 day prior screen . Use rituximab within 12 month prior screen . Change dose frequency , concentration , apply surface area topical steroid , tacrolimus , and/or pimecrolimus within 4 week prior screen . Active severe central nervous system lupus . SELENASLEDAI 's seizure , psychosis , organic brain syndrome , visual disturbance , cranial nerve disorder , lupus headache , cerebrovascular accident ( CVA ) , vasculitis , arthritis , myositis , mucosal ulcer , pleurisy , pericarditis , fever score &gt; 8 total . Active lupus nephritis ( spot protein / creatinine ratio &gt; 1.0 mg/mg ) . End stage renal disease ( estimate glomerular filtration rate [ eGFR ] &lt; 20 ml/min/1.73m^2 use CKDEPI equation [ 53 ] ) . Drug induce lupus . Hemoglobin &lt; 10 g/dL . White blood cell ( WBC ) count &lt; 2,500/ mm^3 ( equivalent &lt; 2.5 x109/L ) . Lymphocyte count &lt; 625/mm^3 ( equivalent &lt; 0.625 x109/L ) . Absolute neutrophil count &lt; 1,500/mm3 ( equivalent &lt; 1.5 x109/L ) . Platelets &lt; 75,000/mm^3 ( equivalent &lt; 75 x 109/L ) . Liver function test ( aspartate aminotransferase [ AST ] , alanine aminotransferase [ ALT ] , alkaline phosphatase [ ALK ] ) result ≥ 2 time upper limit normal ( ULN ) . Direct bilirubin &gt; ULN . Active bacterial , viral , fungal , opportunistic infection require systemic antiinfective therapy . Presence positive purify protein derivative tuberculin skin test ( PPD , &gt; 5mm induration [ regardless Bacille Calmette Guerin ( BCG ) vaccine administration ] ) positive indeterminate QuantiFERON ( R ) TB Gold InTube Test ( QFTG_IT ) screening . Evidence infection human immunodeficiency virus ( HIV ) , hepatitis B ( assess HBsAg antiHBc ) hepatitis C. Detectable circulate EBV cytomegalovirus ( CMV ) genomes active infection . Chronic infection currently treat suppressive antiinfective therapy , include limited tuberculosis , pneumocystis , CMV , herpes zoster , atypical mycobacteria . Herpes simplex virus infection require chronic , suppressive therapy antiviral medication . Receipt liveattenuated vaccine within 12 month prior screen . Concomitant malignancy history malignancy , exception adequately treat basal squamous cell carcinoma skin , carcinoma situ cervix . Pregnancy . Breastfeeding . Unwilling unable use reliable method ( ) contraception four week prior Day 0 throughout three month Treg dosing ( male ) two year Treg dose ( female ) . Note : investigator female participant childbearing potential concurrent MMF , participant , whether plan become pregnant , strongly encourage participate Mycophenolate Risk Evaluation Mitigation Strategy ( REMS ) . Use experimental therapeutic agent within calendar year prior screen . Use biologic medication rituximab within 90 day 5 halflives , whichever great , prior screening . Concomitant medical condition place subject risk participate study , include limited : another severe , systemic autoimmune disease condition ( besides lupus ) require systemic immunosuppressive therapy ( e.g. , rheumatoid arthritis , systemic sclerosis , primary Sjogren 's syndrome , primary vasculitis , psoriasis , multiple sclerosis , ankylose spondylitis , inflammatory bowel disease ) , severe , progressive , poorly control renal , hepatic , hematological , gastrointestinal , pulmonary , cardiac , neurological disease , either relate unrelated SLE , history significant infection recurrent infection , investigator 's opinion , place subject risk participate study concomitant medical condition , investigator 's opinion , place subject risk participating study . Comorbidities require glucocorticoid therapy , include require three course systemic glucocorticoid within previous 12 month . Current history within past year substance abuse . Inability comply study followup procedure .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Tregs</keyword>
</DOC>